Clinical trials: Overweight With Comorbidities
Obesity, Overweight
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are…
- Trial name
- NCT06525935
- Testing
- Enicepatide
- Where
- 34 sites in United States
- Volunteers
- 469 people
- Sponsor
- Carmot Therapeutics, Inc.
Mild Cognitive Impairment, Obesity
Caloric Restriction in Obese Patients With Mild Cognitive Impairment: Effects on Adiposity, Comorbidity and Cognition
Obesity has been associated with cognitive impairments, lower blood flow, metabolic activity and brain volume. Obesity in adulthood is a risk factor for Alzheimer's disease in the elderly.
- Trial name
- NCT01286389
- Testing
- medical care, caloric restriction
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- University of Sao Paulo General Hospital
Obesity or Overweight
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity
A Phase IIb, global, randomized, parallel-group, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of AZD5004 compared with placebo, given once daily as an oral tablet(s) for 36 weeks, in male…
- Trial name
- VISTA (NCT06579092)
- Testing
- AZD5004
- Where
- 62 sites in United States, Australia and 5 more
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Obesity
Interdisciplinary Weight Loss Therapy Associate With the Use of Interactive Digital Technology
Obesity is a complex disease associate to metabolic alterations, which may lead to cardiometabolic risk in women with obesity. The use of interactive digital technology as adjuvante tool to the clinical practices in weight loss…
- Trial name
- NCT04034472
- Testing
- Interdisciplinary intervention in obesity
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- Federal University of São Paulo
Binge Eating Disorder, Cognitive Therapy/Methods
The Psychological Treatment of Overweight Binge Eaters Minority Supplement
Cognitive-behavioral therapy (CBT) has documented efficacy for the treatment of binge eating disorder (BED). Interpersonal psychotherapy (IPT) has been shown to reduce binge eating but its long-term impact and time course on…
- Conditions
- Binge Eating Disorder, Cognitive Therapy/Methods, Mental Disorders/Epidemiology, Obesity/Epidemiology
- Trial name
- NCT01208259
- Testing
- Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT)
- Where
- United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Obesity
Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities
The main purpose of this study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability.
- Trial name
- ZUPREME (NCT06662539)
- Testing
- Petrelintide
- Where
- 32 sites in United States, Poland and 1 more
- Volunteers
- 493 people
- Sponsor
- Zealand Pharma
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight.
- Conditions
- Obesity, Overweight, Metabolism and Nutrition Disorder
- Trial name
- SURMOUNT-CN (NCT05024032)
- Testing
- Tirzepatide
- Where
- 29 sites in China
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Obesity or Overweight
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for…
- Trial name
- ASCEND (NCT06862791)
- Testing
- AZD9550, AZD6234
- Where
- 53 sites in United States, Australia and 3 more
- Volunteers
- 377 people
- Sponsor
- AstraZeneca
Depression, Depressive Disorder
Metformin as Adjunct Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluation
The patients with depression and obesity will receive add-on metformin with antidepressant therapy, which may result in greater improvement in depressive symptoms and BMI reduction compared to antidepressant monotherapy.
- Conditions
- Depression, Depressive Disorder, Overweight or Obesity, Depressive Symptoms
- Trial name
- NCT07654179
- Testing
- Metformin, Antidepressant Therapy
- Where
- 2 sites in Pakistan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Riphah International University
Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
The aim of the study is to evaluate the safety and efficacy of Ecnoglutide injection in overweight or obese Chinese adolescents
- Trial name
- NCT07836270
- Testing
- Ecnoglutide Injection
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity, Overweight and Obesity
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.
- Trial name
- NCT05051579
- Testing
- LY3502970
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 272 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide, on body weight loss after 48 weeks of treatment in adults with obesity or…
- Conditions
- Obesity, Overweight, Overweight With One Weight Related Comorbidity
- Trial name
- GYMINDA (NCT06965413)
- Testing
- RO7204239, Tirzepatide
- Where
- 35 sites in United States, Poland and 2 more
- Volunteers
- 285 people
- Sponsor
- Hoffmann-La Roche
Obesity, Overweight
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
Study ASC30-301 (AURORA-1) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral…
- Conditions
- Obesity, Overweight, Chronic Weight Management
- Trial name
- AURORA-1 (NCT07743463)
- Testing
- ASC30 tablets A1
- Where
- 122 sites in United States, Canada and 5 more
- Volunteers
- 3,003 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Overweight, Obesity
Observational, Real-life, Retrospective, Data Collection, Use Sibutramine/topiramate in Overweight Comorbidities/obesity
An observational, multicenter, national study with retrospective real-life data collection on the combined treatment of sibutramine and topiramate (off-label use) for the treatment of overweight with comorbidity(ies) or obesity.
- Trial name
- TOLERASIT (NCT05209997)
- Testing
- Source document data collection
- Where
- 2 sites in Brazil
- Sponsor
- Eurofarma Laboratorios S.A.
Obesity, Overweight
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2…
- Trial name
- NCT06972459
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 800 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The purpose of this study is to identify the weekly oral dose of VRB-101 (oral ecnoglutide) that can effectively maintain body weight in participants with a history of obesity or overweight with weight-related comorbidities.
- Conditions
- Obesity, Overweight, Weight Maintenance
- Trial name
- NCT07553299
- Testing
- VRB-101
- Where
- 20 sites in United States
- Volunteers
- 8 people
- Sponsor
- Verdiva Bio Dev Limited
Obesity, Overweight
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity.
- Trial name
- NCT06075667
- Testing
- Tirzepatide
- Where
- 33 sites in United States, Canada and 4 more
- Volunteers
- 160 people
- Sponsor
- Eli Lilly and Company
Morbid Obesity
Effect of Long Biliopancreatic Limb RYGB on Weight Loss and Comorbidities
Morbid obesity is an increasing medical problem in the western countries. It's related to comorbidities as diabetes mellitus, hypertension, OSAS, arthrosis and hypercholesterolemia.
- Trial name
- Elegance (NCT01686997)
- Testing
- Roux-en-Y Gastric Bypass
- Where
- Netherlands
- Volunteers
- 280 people
- Sponsor
- Rijnstate Hospital
Asthma Bronchiale, Breast Neoplasms
Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity
The web application gp-multitool.de is a digital tool for implementing the German S3 clinical practice guideline for multimorbidity of the German Society of General Practitioners and Family Physicians in primary care.
- Conditions
- Asthma Bronchiale, Breast Neoplasms, Coronary Disease, Diabetes Mellitus, Type 2
- Trial name
- NCT06831994
- Testing
- gp-multitool.de
- Where
- Germany
- Volunteers
- 659 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Obesity, Overweight
A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.
The purpose of this study is to collect information about the safety and effectiveness of Saxenda® in obese patients and overweight patients with obesity-related comorbidities.
- Trial name
- NCT03560336
- Testing
- Liraglutide
- Where
- 28 sites in South Korea
- Volunteers
- 758 people
- Sponsor
- Novo Nordisk A/S